Novartis Q2 sales rise 3% to $14.4 billion

• Novartis reported Q2 net sales of $14.41 billion, up 3% in reported currencies.
• Core operating income remained flat at $5.94 billion, while net income fell 19%.
• The company reaffirmed its 2026 guidance and reported progress across several drug programmes.

Novartis (NYSE:NVS) reported Q2 2026 net sales of $14.41 billion, up 3% in dollars and 1% at constant currencies.

Sales increased from $14.05 billion, while core operating income of $5.94 billion exceeded the $5.31 billion analyst estimate.

Operating income fell 2% to $4.75 billion, net income dropped 19% to $3.26 billion, and free cash flow declined 12% to $5.56 billion.

Following the announcement, Novartis' share price was up 2.18% at CHF 125.78 as the company reaffirmed its 2026 guidance.

Meanwhile, Novartis is focusing its investment on oncology, immunology, neuroscience, cardiovascular-renal-metabolic medicines, gene and cell therapy, radioligand therapy, and xRNA.

Recent moves include the $12 billion Avidity acquisition, the planned Myricx Bio purchase, Fabhalta approval, Rhapsido and Itvisma approvals, and del-zota’s FDA filing.